The results of the STEADY-PD Phase III clinical trial results for Parkinson's have been released. The trial had been testing the blood pressure medication Isradipine for its ability to slow the progression of Parkinson's. The announced results are disappointing, suggesting that the treatment did not show any benefit for people with Parkinson's.

This National Institute of Neurological Disorders and Stroke funded trial (NINDS) which was based on strong supportive preclinical data - involved more than 330 participants with recently diagnosed Parkinson's in a multi-centre study, conducted at 56 research sites across the US and Canada. The participants took the Isradipine medication(or a placebo) daily for 3 years, and were clinically assessed throughout the study.

The Cure Parkinson's Trust (CPT) was not involved in this study, but did fund some of the early preclinical research that led to this trial. The full results of the clinical trial are yet to be published, so no further conclusions can be made at this stage. 

Helen Matthews, Deputy CEO, CPT said:

The STEADYPD results are of course disappointing, particularly as the preclinical, phase II, epidemiological findings that informed the phase III trial were encouraging and Isradipine would have been an easy drug to add into the treatment plans of people living with Parkinson’s.  When studies do not reach their primary end point, it is important to ensure that key findings inform clinical trials in the future, as we will only be able to develop new treatments for people living with Parkinson’s by conducting clinical trials.

Dr Simon Stott, Deputy Director of Research, CPT said:

Obviously it is disappointing for all of the Parkinson's community that this large clinical trial has not demonstrated benefits for individuals affected by the condition, but we will be awaiting the publication of the full results to determine what else can be learnt from the study and what positives can be taken away.

Further reading: